Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier

Nanomedicine

Volumn 6, Issue 3, 2011, Pages 423-436

  Tosi, Giovanni ^a   Fano, Rita Adriana ^a   Bondioli, Lucia ^a   Badiali, Luca ^a   Benassi, Rois ^a   Rivasi, Francesco ^a   Ruozi, Barbara ^a   Forni, Flavio ^a   Vandelli, Maria Angela ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

BBB crossing; biodistribution; nanotechnology; neuroscience; pharmacology

Indexed keywords

GLYCOPEPTIDE; HEPTAPEPTIDE; LOPERAMIDE; NANOPARTICLE; POLYGLACTIN; POLYLACTIDE CO GLYCOLIDE GLYCOHEPTAPEPTIDE CONJUGATED NANOPARTICLE; RHODAMINE 123; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONFORMATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; ENDOCYTOSIS; MALE; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; GLYCOPEPTIDES; LACTIC ACID; LOPERAMIDE; MALE; NANOPARTICLES; NEURODEGENERATIVE DISEASES; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; RHODAMINE 123; TISSUE DISTRIBUTION;

EID: 79955583887     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.11.11     Document Type: Article

References (38)

1. World Health Organization: Neurological disorders: Public health challenges. Geneva, 2006
2. Pardridge WM: Why is the global CNS pharmaceutical market so under-penetrated? Drug Disc. Today 7, 5-7 (2002) n Good evaluation of the CNS pharmaceutical market, with updated data and comment on future evolution. (Pubitemid 34093938)
3. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA: Polymeric nanoparticles for the drug delivery to the central nervous system. Exp. Opin. Drug. Del. 5, 155-174 (2008). nn Overall vision of nanoparticle (NP) use for CNS drug delivery. (Pubitemid 351308309)
4. Polt R, Palian MM: Glycopeptide analgesics. Drugs Future 26, 561-576 (2001). (Pubitemid 32899671)
5. Tosi G, Costantino L, Rivasi F et al.: Targeting the central nervous system. In vivo experiments with peptide derivatized nanoparticles loaded with loperamide and rhodamine 123. J. Control. Release 122, 1-9 (2007). (Pubitemid 47284547)
6. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L: Nanoparticles as drug delivery agents specific for CNS: In vivo biodistribution. Nanomedicine 5, 369-377 (2009). n In vivo biodistribution of modified and unmodified NPs and intracerebroventricular comparision.
7. Smith MS, Gumbleton M: Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. J. Drug Target. 14, 191-214 (2006).
8. Sahay G, Alakova DY, Kabanov AV: Endocytosis of nanomedicines. J. Control. Rel. 145(3), 182-195 (2010). nn Very complete evaluation of the mechanism of membrane crossing of several kinds of nanoparticulate systems for drug delivery.
9. Zensi A, Begley D, Pontikis C et al.: Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons. J. Control. Rel. 137, 78-86 (2009).
10. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F: Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control. Rel. 108, 84-96 (2005). (Pubitemid 41476677)
11. EEC (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Offical Journal of the European Communities L358, 1-29 (1986).
12. Costantino L, Gandolfi F, Bossy Nobs L et al.: Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures. Biomaterials 27, 4635-4645 (2006). (Pubitemid 43783224)
13. Tosi G, Vergoni AV, Ruozi B et al.: Sialic-acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J. Control. Release 145, 49-57 (2010).
14. Fessi H, PuisieuxF, Devissaguet JP, Ammoury N, Benita S: Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55, R1-R4 (1989). (Pubitemid 19247505)
15. Eddy B, Leimbach D: Synthetic analgesic. II. Dithienylbutyl and dithienylbutylamines. J. Pharm. Exper. Ther. 107, 385-395 (1953). 16 Rezayat M, Rahnavard A, Zarrindast M: Role of cholecystokinin receptors in induction of antinociception in hot-plate test. Pharmacol. Toxicol. 87, 58-62 (2000).
16. Xu Z, Pilch DS, Srinivasan AR, Olson WK, Geacintov NE, Breslauer KJ: Modulation of nucleic acid structure by ligand binding induction of a DNA•RNA•DNA hybrid triplexby DAPI intercalation. Bioorg. Med. Chem. 5, 1137-1147 (1997). (Pubitemid 27264841)
17. Reynold ES: The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J. Cell. Biol. 17, 208-212 (1963).
18. Frisch MJ, Trucks GW, Schlegel HB et al.: Gaussian 03; Gaussian, Inc.: Pittsburgh, PA, USA (2003).
19. Becke AD: Density-functional exchange-energy approximation with correct asymptotic behavior. Phys. Rev. A. 38, 3098-3100 (1988).
20. Lee C, Yang W, Parr RG: Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B. 37, 785-789 (1988).
21. Murray JS: Molecular Electrostatic Potentials: Concepts and Applications; Theoretical and Computational Chemistry Book Series (Volume 3). Elsevier, Amsterdam, The Netherlands (1996).
22. Keyth T, Millam J, Eppinnett K, Hovell WL, Gilliand R: GaussView, version 3.0, Dennington, R., II; Semichem, Inc.; Shawnee Mission, KS, USA (2003).
23. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F: Conjugated poly(d,l-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 26, 4189-4195 (2005). (Pubitemid 40138665)
24. Koziara JM, Lockman PR, Allen DD, Mumper RJ: In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20, 1772-1777 (2003).
25. Pauling L, Corey RB, Branson MR: The structure of proteins: Two hydrogen-bonded helical configurations of the polypeptide chain. Proc. Natl Acad. Sci. USA 37, 205-211 (1951).
26. Polt R: Glycosylated neuropeptides: A new vista for neuopharmacology? Med. Res. Rev. 25, 557-585 (2005). (Pubitemid 41233371)
27. Dhanasekaran M, Palian M, Alves I et al.: Glycopeptides related to β-endorphines adopt helical amphipathic conformation in the presence of lipid bilayers. J. Am. Chem. Soc. 127, 5435-5448 (2005). (Pubitemid 40569855)
28. McMahon HT, Gallop J: Membrane curvature and mechanisms of dynamic cell membrane remodeling. Nature 438, 590-596 (2005). nn Very good evaluation of membrane curvature and mechanisms affecting membrane behavior. (Pubitemid 41740562)
29. Zimmemberg G, Kozlov MM: How proteins produce cellular membrane curvature. Nat. Rev. Mol. Cell Biol. 7, 9-19 (2006). (Pubitemid 43361568)
30. Nassif X, Bourdoulous S, Eugene E, Couraud PO: How do extracellular pathogens cross the blood brain barrier. Trends Microbiol. 10(5), 227-232 (2002). (Pubitemid 34327815)
31. Coureuil M, Mikaty G, Miller F et al.: Meningococcal type IV Pili recruit the polarity complexto cross the brain endothelium. Science 325, 83-87 (2009).
32. Prasadaro NV, Wass CA, Weiser JN, Stins MF, Huang SH, Kim KS: Outer membrane protein A-promoted of Escherichia coli contributes to invasiton of brain microvascular endothelial cell. Infect. Immun. 64, 146-153 (1996). (Pubitemid 26009353)
33. Torchilin VP, Rammohan R, Weissig V, Levchenko TS: TAT-peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in presence of metabolic inhibitors. Proc. Natl Acad. Sci. USA 98, 8786-8791 (2001). (Pubitemid 32678105)
34. Patel LN, Zaro JL, Shen WC: Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24, 1977-1992 (2007). (Pubitemid 47493563)
35. Win KY, Feng SS: Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713-2722 (2005). 37 Calvo P, Gouritin B, Chacun H et al.: Long-circulating PEGyilated polycyanoacrylate nanoparticles as a new drug carrier for brain delivery. Pharm. Res. 18, 1157-1166 (2001). n Research article dealing with long-circulating NPs with in vivo and in vitro experiments.
36. Brigger P, Morizet J, Aubert G et al.: Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303, 928-936 (2002). (Pubitemid 35424373)
37. Costantino L, Tosi G, Ruozi B, Bondioli L, Vandelli MA, Forni F: Colloidal systems for CNS drug delivery, nanoneuroscience and nanoneuropharmacology. Prog. Brain Res. 180, 35-69 (2009). nn Overall vision of the application of surface engineering of nanoparticulate systems for brain delivery.
38. Palian MM, Boguslavsky VI, O'Brien DF, Polt R: Glycopeptide-membrane interactions: Glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media. J. Am. Chem. Soc. 125, 5823-5831 (2003). (Pubitemid 36592908)